What to Know About the Eversense 365 CGM, with Brian Hansen
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
2w ago
On September 17, 2024, Ascensia Diabetes Care and Senseonics announced the US Food and Drug Administration's (FDA) clearance of the Eversense 365 system for people with type 1 and type 2 diabetes aged 18 years or older—the world’s first 1-year continuous glucose monitor (CGM). A fully implantable, long-term CGM option, the Eversense 365 offers a 12-month sensor survivability and implantable sensor, which allow for fewer data interruptions, less waste, and lessened burden on quality of life, according to the release from Ascensia and Senseonics. Other features highlighted by the companies incl ..read more
Visit website
Lingo Availability & Embecta's Tubeless Patch Pump
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
2w ago
In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss US availability of the Abbott Lingo and Embecta’s announcement of US Food and Drug Administration (FDA) clearance for their tubeless patch pump with a 300-unit insulin reservoi ..read more
Visit website
Real-World Experience with Dexcom Stelo
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
2w ago
In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into their experience with the Dexcom Stelo. The Dexcom Stelo is the first FDA-cleared over-the-counter glucose sensor. Cleared by the FDA on March 05, 2024, the Stelo is indicated for use by anyone 18 years and older who does not use insulin, such as individuals with diabetes treating their condition with oral medications, or those without diabetes who want to better understand how diet and exercise may impact blood sugar levels ..read more
Visit website
Sotagliflozin for T1D and Other ADCES Highlights
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
2w ago
This episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, our second related to the Association of Diabetes Care and Education Specialists (ADCES) 2024 annual meeting, spotlights new data and perspectives from the meeting brought forth by pharmaceutical and diabetes technology companies. Check out our first episode related to ADCES 2024. A large theme of the episode is discussion around data and interactions with Lexicon, which announced the resubmission of a New Drug Application for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic cont ..read more
Visit website
PROTECT Data and Teplizumab in Newly Diagnosed T1D
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
2w ago
In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes ..read more
Visit website
First 10 Prices Announced from CMS Price Negotiations
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
2M ago
On August 15, 2024, the Biden-Harris Administration announced the price list for the first 10 drugs selected as part of the Medicare price negotiations between the United States Department of Health and Human Services (HHS) and pharmaceutical manufacturers. “Americans pay too much for their prescription drugs. That makes today’s announcement historic. For the first time ever, Medicare negotiated directly with drug companies and the American people are better off for it,” said HHS Secretary Xavier Becerra. Part of the Inflation Reduction Act, the announcement of intended pricing for these agent ..read more
Visit website
SUMMIT and FINEARTS-HF, with Muthiah Vaduganathan, MD, MPH
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
3M ago
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP,  welcome Muthiah Vaduganathan, MD, MPH, cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials, the latter of which Vaduganathan served on as a trial investigator. Video Version: https://www.hcplive.com/view/diabetes-dialogue-summit-and-finearts-hf-with-muthiah-vaduganathan-md-mph SUMMIT On August 01, 2024, Eli Lilly and Company announced topline data from the SUMMIT trial ..read more
Visit website
Simplera CGM and Medtronic's Partnership with Abbott
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
3M ago
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, take a break from the Annual Conference of the Association of Diabetes Care and Education Specialists to discuss the latest news from Medtronic and what it means for practitioners as ..read more
Visit website
CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
3M ago
Even with the second half of the trial yet to be completed, results of the CATALYST trial have initiated a potentially seismic shift in discussions around the management of type 2 diabetes. With the first part of the trial suggesting approximately 1-in-4 patients with difficult-to-control type 2 diabetes, results suggest hypercortisolism could be an underlying driver of suboptimal disease management for millions of people with type 2 diabetes in the US. Now, with this knowledge in hand, the community waits with bated breath for Corcept Therapeutics’ announcement of results from the second half ..read more
Visit website
INHALE-3 and Diabetes Tech Updates, with Grazia Aleppo, MD
Diabetes Dialogue
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
3M ago
At the 84th American Diabetes Association (ADA) Scientific Sessions, INHALE-3 was among the trials to take center stage. A phase 4 trial comparing the use of inhaled insulin (Afrezza) against standard care, results demonstrated use of inhaled insulin, in addition to insulin degludec, was associated with improved HbA1c in patients with type 1 diabetes, with an improvement of 0.5% or greater observed among 21% of those on inhaled insulin and 5% of those with usual care. At the meeting, study investigator Grazia Aleppo, MD, professor of Medicine and director of the Diabetes Center at Northwestern ..read more
Visit website

Follow Diabetes Dialogue on FeedSpot

Continue with Google
Continue with Apple
OR